BridgeMD
Tests treatment safety and results for Von Willebrand Disease (VWD), Type 2
Official title Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease
ClinicalTrials.gov ID: NCT07273721
What this study is testing
What is BT200?
BT200 is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for von willebrand disease (vwd), type 2.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This randomized clinical trial with a cross-over design is being conducted at the Department of Clinical Pharmacology at the Medical University of Vienna, and a total of 4-6 patients with type 2B von Willebrand disease (VWD) will participate. The main purpose of this clinical trial is to investigate the efficacy and safety of BT200, a new drug for thrombocytopenic patients with type 2B von Willebrand disease (VWD).
- Phase 2: a mid-size study of how well it works
- Time commitment: about 4 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ≥18 years old
- Type 2B VWD with thrombocytopenia and a recent bleeding history (e.g. recurrent haematomas)
- Able to comprehend and to give informed consent
- Able to cooperate with the Investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related...
You likely can't join if
- Clinically significant medical history or ongoing chronic illness that would jeopardise the safety of the patient or compromise the quality of the...
- History of significant drug allergy or anaphylactic reactions
- Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the Investigator for the patient to be able to comply fully...
- Use of medication during 2 weeks before the start of the study, which in the judgment of the Investigator may adversely affect the patient's welfare...
- Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5...
The study team makes the final eligibility decision.
Where it's taking place
- Vienna, State of Vienna, Austria
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 4 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Vienna, State of Vienna, Austria. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.